Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

teriflunomide

- PMLiVE

Genzyme shocked by FDA’s rejection of Lemtrada

US regulator refuses to approve MS drug on safety grounds

- PMLiVE

ABPI reprimands for four pharma firms

Allergan, Shire Pharmaceuticals, Gedeon Richter and Sanofi breach Code of Practice

Ireland unveils eHealth strategy

Will recruit chief information officer to run new eHealth entity

- PMLiVE

Sanofi’s Aubagio backed by NICE

Oral MS drug recommended for NHS use in England and Wales

National Institute for Health and Care Excellence NICE logo

NICE wants more info on Genzyme’s MS drug

UK health guidance body turns down Lemtrada in draft guidance

Sanofi reception

Sanofi’s Lantus successor on track

Positive late-stage data for U300 insulin in type 2 diabetes patients

- PMLiVE

Sanofi wins two at PMEA 2013

Awards haul also includes four high commendations

Biogen Idec building

Biogen Idec wins EU battle on Tecfidera exclusivity

Oral MS drug gains New Active Substance status

Sanofi reception

Sanofi moves closer to arthritis drug filing

Reports positive late-stage results for sarilumab

Sanofi reception

Sanofi pulls development of blood cancer drug

Fedratinib linked to brain disorder during clinical trials

- PMLiVE

Sales down at Merck Serono on Rebif pressure

New MS drugs impact pharma company’s revenues

Sanofi reception

Sanofi returns to growth in Q3

Diabetes products and Genzyme help company overcome patent cliff

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links